Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study.
Between 1999 and 2002, 496 invasive group A streptococcal (GAS) isolates from clinical microbiological departments in Denmark and subsequently 487 (98%) questionnaires from the clinicians treating the patients were received as part of a national surveillance. emm types and streptococcal superantigen (SAg) genes were determined. The incidence of invasive GAS infections was on average 2.3 per 100,000 per year. Bacteremia with no focal symptoms (27%) was together with erysipelas (20%) the most prevalent clinical diagnoses. Streptococcal toxic shock syndrome occurred in 10% of patients, of which 56% died. The overall case fatality rate within 30 days was 23%. In total, 47 different emm types were identified, of which emm1, emm3, emm4, emm12, emm28, and emm89 were identified in 72% of the 493 available isolates. During the 4-year period the presence of emm1 increased from 16% in 1999 to 40% in 2002. Concurrently, the presence of emm3 decreased from 23% in 1999 to 2% in 2002. The emm1 isolates predominantly carried speA, although the frequency decreased from 94% in 1999 to 71% in 2002, whereas the emm1-specific prevalence of speC increased from 25 to 53%. In a historical perspective, this could be interpreted as a reemergence of emm1 and could indicate a possible introduction of a new emm1 subclone. However, this reemergence did not result in any significant changes in the clinical manifestations during the study period. Our results show the complexity of invasive GAS infections, with time-dependent variations in the incidence and distribution of emm and SAg genes, which emphasizes the need for continuous epidemiological and molecular investigations.
Ekelund
Kim
K
Streptococcus Unit, Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S., Denmark. kej@ssi.dk
Skinhøj
Peter
P
Madsen
Jesper
J
Konradsen
Helle Bossen
HB
D000942:Antigens, Bacterial / Q000235:genetics*; D016470:Bacteremia / Q000453:epidemiology / Q000382:microbiology; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics*; D002352:Carrier Proteins / Q000235:genetics*; D003718:Denmark / Q000453:epidemiology; D004886:Erysipelas / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D006801:Humans; D015994:Incidence; D016133:Polymerase Chain Reaction; D011644:Puerperal Disorders / Q000453:epidemiology / Q000382:microbiology; D012772:Shock, Septic / Q000453:epidemiology / Q000382:microbiology; D018461:Soft Tissue Infections / Q000453:epidemiology / Q000382:microbiology; D013290:Streptococcal Infections / Q000453:epidemiology* / Q000382:microbiology / Q000401:mortality / Q000503:physiopathology; D013297:Streptococcus pyogenes / Q000145:classification* / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D018089:Superantigens / Q000235:genetics*
D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D002352:Carrier Proteins; D018089:Superantigens; C014689:streptococcal M protein